KALA News and Press, Kala Pharmaceuticals Inc. From 12/30/22

Palm Beach, FL – December 30, 2022 – FinancialNewsMedia.com News Commentary – According to the Centers for Disease Control and Prevention, arthritis affects approximately one in every four Americans, or 58.5 million people. The global rheumatoid arthritis drugs market is ...

Shares of Kala Pharmaceuticals ( NASDAQ: KALA ) more than tripled in value on Wednesday, a day after the U.S. Food and Drug Administration accepted an investigational new drug (IND) application by the company. KALA stock closed 218.4% higher at $12.48. The micro-cap clinical-s...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid another soft performance for the benchmark equities index, rare-eye disease specialist Kala Pharmaceuticals (NASDAQ: KALA ) lit up the overcast sky with a stunning triple-digit performance. Yesterday afternoon, the com...

Kala Pharmaceuticals ( NASDAQ: KALA ) on Tuesday said the U.S. Food and Drug Administration (FDA) had accepted its investigational new drug application for its lead product candidate KPI-012 for the treatment of persistent corneal epithelial defect (PCED). Shares of the micro-cap clin...

-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a...

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, due upon FDA acceptance of KPI-012 IND -- ARLINGTON, Mass., Nov. 28, 2022 (G...

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it has entered int...

Kala Pharmaceuticals ( NASDAQ: KALA ), a company focused on treatments for eye diseases, rose ~33% in the morning hours Wednesday after its management brought more clarity to the development of its eye disease candidate KPI-012 with its Q3 2022 results. KPI-012 is an...

Kala Pharmaceuticals press release ( NASDAQ: KALA ): Q3 GAAP EPS of $19.25. Revenue of $0.42M (-86.3% Y/Y). As of September 30, 2022, Kala had cash and cash equivalents of $52.4 million, compared to $44.6 million of cash and cash equivalents as of June 30, 2022. ...

-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficient for Funding Operations into 2Q 2024 -- ARLINGTON, Mass., Nov. 08, 2022 (GL...